The results from the clinical trials conducted in 499 study participants showed that patients treated with REGN-EB3 or mAb114 had a greater chance of survival when compared to those treated with the two other drugs.
Majibu ya majaribio ya kitabibu conducted kwa washiriki 499 wa utafiti yalionesha kuwa wagonjwa waliotibiwa kwa REGN-EB3 au mAb114 walionesha kuwa na nafasi kubwa ya kupona ukilinganisha na wale waliotibiwa kwa dawa nyingine mbili.